Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization

Cancer Research

Volumn 66, Issue 20, 2006, Pages 10136-10144

  Yagi, Hiroaki ^a   Hashizume, Hideo ^a   Horibe, Takahiro ^a   Yoshinari, Yasushi ^a   Hata, Maki ^a   Ohshima, Akihiro ^a   Ito, Taisuke ^a   Takigawa, Masahiro ^a   Shibaki, Akihiko ^b   Shimizu, Hiroshi ^b   Seo, Naohiro ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; IMMUNOMODULATING AGENT;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HLA SYSTEM; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; MALE; MELANOMA; PERCUTANEOUS PEPTIDE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRATUM CORNEUM; UPREGULATION; VITILIGO;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANTIGENS, NEOPLASM; CELL MOVEMENT; EPITOPES, T-LYMPHOCYTE; FOLLOW-UP STUDIES; HUMANS; INTERFERON TYPE II; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33750561918     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1029     Document Type: Article

References (50)

1. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
2. Kundu SK, Dupuis M, Sette A, et al. Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization. AIDS Res Hum Retroviruses 1998;14:1669-78.
3. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
4. + regulatory T cells in vivo in humans. Blood 2002;100: 174-7.
5. + T-cell in humans without foreign helper epitopes. J Clin Invest 2000;105:R9-14.
6. + progenitor derived dendritic cells. J Exp Med 2004;199:1503-11.
7. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, eryopreserved, peptide-ioaded monocyte-derived dendritic cells. J Exp Med 2002;195: 1279-88.
8. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001;106: 271-4.
9. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001;93:243-51.
10. de Vries IJ, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003;63:12-7.
11. de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003;9:5091-100.
12. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-80.
13. Engleman EG. Dendritic cell-based cancer immunotherapy. Semin Oncol 2003;30:23-9.
14. Jakob T, Udey MC. Epidermal Langerhans cells: from neurons to nature's adjuvants. Adv Dermatol 1999;14: 209-58.
15. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18: 767-811.
16. Raz E, Carson DA, Parker SE, et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci U S A 1994;91:9519-23.
17. Bouloc A, Walker P, Grivel JC, Vogel JC, Katz SI. Immunization through dermal delivery of protein-encoding DNA: a role for migratory dendritic cells. Eur J Immunol 1999;29:446-54.
18. Granstein RD, Ding W, Oxawa H. Induction of antitumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J Invest Dermatol 2000;114:632-6.
19. Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 2004;113: 998-1007.
20. Seo N, Tokura Y, Nishijima T, Hashizume H, Furukawa F, Takigawa M. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc Natl Acad Sci U S A 2000;97:371-6.
21. Nishijima T, Tokura Y, Imokawa G, Seo N, Furukawa F, Takigawa M. Altered permeability and disordered cutaneous immunoregulatory function in mice with acute barrier disruption. J Invest Dermatol 1997;109: 175-82.
22. Godefroy S, Peyre M, Garcia N, Muller S, Sesardic D, Partidos CD. Effect of skin barrier disruption on immune responses to topically applied cross-reacting material, CRM197, of diphtheria toxin. Infect Immun 2005;73:4803-9.
23. Nagatani T, Ichiyama S, Onuma R, et al. The use of DAV (DTIC, ACNU and VCR) and natural interferon-β combination therapy in malignant melanoma. Acta Derm Venercol 1995;75:494.
24. Sliz P, Michielin O, Cerottini JC, et al. Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. J Immunol 2001;167:3276-84.
25. Yagi H, Tokura Y, Furukawa F, Takigawa M. Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliteraHve disorders: successful treatment with recombinant interferon-γ. J Invest Dermatol 1996;107:827-32.
26. Cooper KD, Fox P, Neises G, Katz SI. Effects of ultraviolet radiation on human epidermal cell alloantigen presentation: initial depression of Langerhans cell-dependent function is followed by the appearance of T6- Dr+ cells that enhance epidermal alloantigen presentation. J Immunol 1985;134: 129-37.
27. Yu RC, Abrams DC, Alaibac M, Chu AC. Morphological and quantitative analyses of normal epidermal Langerhans cells using confocal scanning laser microscopy. Br J Dermatol 1994;131:843-8.
28. + Th2 cells mediate UVB-induced suppression of murine contact photosensitivity by releasing IL-10. J Immunol 1996;156:1824-31.
29. Hashizume H, Takigawa M, Tokura V. Characterization of drug-specific T cells in phenobarbital-induced eruption. J Immunol 2002;168:5359-68.
30. + T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 2001;98:1872-81.
31. + T-regulatory cells and systemic collapse of antitumour immunity. Immunology 2001;103:449-57.
32. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
33. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002;23:445-8.
34. + dendritic cells but not by Langerhans cells. Science 2003;301:1925-8.
35. Zhao X, Deak E, Soderberg K, et al. Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J Exp Med 2003;197:153-62.
36. Bennett CL, van Rijn E, Jung S, et al. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol 2005;169: 569-76.
37. Kaplan DH, Jenison MC, Saeland S, Shlomchik WD, Shlomchik MJ. Epidermal Langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 2005;23:611-20.
38. Kissenpfennig A, Henri S, Dubois B, et al. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 2005;22: 643-54.
39. Guebre-Xabier M, Hammond SA, Epperson DE, Yu J. Ellingsworth L, Glenn GM. immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J Virol 2003;77:5218-25.
40. Frech SA, Kenney HT, Spyr CA, et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 2005;23:946-50.
41. Fan H, Lin Q, Morrissey GR, Khavari PA. Immunization via hair follicles by topical application of naked DNA to normal skin. Nat Biotechnol 1999;17:870-2.
42. Morel PA, Falkner D, Plowey J, Larregina AT, Falo LD, Jr. DNA immunisation: altering the cellular localisation of expressed protein and the immunisation route allows manipulation of the immune response. Vaccine 2004;22: 447-56.
43. Roy MJ, Wu MS, Barr LJ, et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000;19:764-78.
44. Chen D, Payne LG. Targeting epidermal Langerhans cells by epidermal powder immunization. Cell Res 2002; 12:97-104.
45. Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med 2002;8:415-9.
46. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host tumor immune conflict: from immunosuppression to resistance and destruction. Immunology Today 1997;18:493-7.
47. Strand S, Galle PR. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today 1998;4:63-8.
48. Ko EC, Wang X, Ferrone S. Immunotherapy of malignant diseases. Challenges and strategies. Int Arch Allergy Immunol 2003;132:294-309.
49. Guboa E. The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol 2001;2:789-92.
50. Lane C, Leitch J, Tan X, Hadjati J, Bramson JL, Wan Y. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res 2004;64:1509-14.